SPDR S&P Pharmaceuticals ETFXPH
XPH
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1% less funds holding
Funds holding: 71 [Q2] → 70 (-1) [Q3]
6.31% less ownership
Funds ownership: 59.07% [Q2] → 52.76% (-6.31%) [Q3]
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
11% less capital invested
Capital invested by funds: $110M [Q2] → $98M (-$12.2M) [Q3]
29% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 24
38% less call options, than puts
Call options by funds: $834K | Put options by funds: $1.35M
Research analyst outlook
We haven’t received any recent analyst ratings for XPH.
Financial journalist opinion
Positive
Zacks Investment Research
4 months ago
Pharma ETFs in Focus Post Solid Q2 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Neutral
Zacks Investment Research
4 months ago
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
The SPDR S&P Pharmaceuticals ETF (XPH) was launched on 06/19/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Neutral
Zacks Investment Research
5 months ago
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on 06/19/2006.
Neutral
ETF Trends
6 months ago
Finding Opportunity in Unloved Healthcare ETFs
Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?
Neutral
Zacks Investment Research
7 months ago
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on 06/19/2006.
Positive
Zacks Investment Research
7 months ago
5 Beaten-Down Top-Ranked ETFs to Buy for a Turnaround
We have highlighted five ETFs from different zones that have plunged the most so far this year but have a solid Zacks ETF Rank.
Positive
Zacks Investment Research
7 months ago
A Look at Pharma ETFs Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Positive
Seeking Alpha
8 months ago
XPH: A More Balanced Way To Get Exposure To Pharmaceuticals
The SPDR S&P Pharmaceuticals ETF offers broad-based exposure to the U.S. pharmaceuticals sector, making it a good option for investing in the industry. XPH tracks the performance of the S&P Pharmaceuticals Select Industry Index and provides a cost-effective way to gain exposure to the sector. The top holdings of XPH include Axsome Therapeutics, Eli Lilly, Merck & Co., Pfizer, and Jazz Pharmaceuticals, offering diversification and potential for growth within the pharmaceutical sector.
Neutral
Zacks Investment Research
10 months ago
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
Making its debut on 06/19/2006, smart beta exchange traded fund SPDR S&P Pharmaceuticals ETF (XPH) provides investors broad exposure to the Health Care ETFs category of the market.
Neutral
Zacks Investment Research
10 months ago
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on 06/19/2006.
Charts implemented using Lightweight Charts™